Skip to main content
Equibles
LRMR logo

LRMR · Larimar Therapeutics, Inc.

Track LRMR — free

Use LRMR with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about LRMR

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$4.16 +0.11 (+2.72%) At close · Aug 25
Going-concern doubt — flagged Aug 4, 2026

Substantial doubt about the company's ability to continue as a going concern.

“these cash resources are not sufficient to fund the Company's planned operations for a period of at least one year from the date these unaudited condensed consolidated financial statements are issued. ... There is no assurance, however, that additional financing will be available when needed or that the Company will be able to obtain financing on terms acceptable to the Company. ... These conditions raise substantial doubt about the Company's ability to continue as a going concern.”
View the 10-Q filed Aug 4, 2026
Market Cap
$421.97M
Shares
103.88M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$4.16 Open$4.08 Day$4.08–4.24 52W close$2.81–5.95 Avg vol 30d1.2M Short int13.4M · 12.9% float · 11.2d Short vol57% Last earningsMay 15, 2023 DataJan 2020–Aug 2026 Filing10-Q · Aug 4

Up next

FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 4, 2026

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Buy Momentum Neutral Sentiment Neutral Fundamentals Weak Quant / Vol Very High
Market backdrop VIX 15.5 · calm Equity put/call 0.57
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg +6%
above
Price vs 50-day avg +8%
above
RSI (14) 53
neutral
MACD trend Negative
52-week position 43%
mid-range
Momentum
relative strength
Neutral
1-month return +9%
trailing
6-month return −24%
trailing
YTD return +9%
this year
Relative strength −35%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $4 › 200d $4 — 200d above 50d
Institutional flow Distributing
-1% holders QoQ · +32 funds added
Insider flow Accumulating
Net +$166.9K over 90 days · 0% sells
Short interest Rising
12.94% of float · ▲ +10.3% MoM · 11.2 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
161 holders — near 3-yr high, broad support
Squeeze score 75
high risk · 0–100
Fundamentals
Weak
EPS growth −57%
Y/Y
Free cash flow $-113.3M
Balance sheet $70.9M
net cash
Quant / Vol
risk profile
Very High
Volatility 109%
annualized · 1-yr
Max drawdown −49%
past year
ATR 5.8%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Buy
1 · 3 · 2
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+6% Bullish
Price vs 50-day avg
+8% Bullish
RSI (14)
53 Neutral
MACD trend
Negative Bearish
52-week position
43% Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50d $4 › 200d $4 — 200d above 50d
Institutional flow Distributing
-1% holders QoQ · +32 funds added
Insider flow Accumulating
Net +$166.9K over 90 days · 0% sells
Short interest Rising
12.94% of float · ▲ +10.3% MoM · 11.2 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
161 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $3 Now $4 · 43% Range high $6
vs 200-day avg +6% vs 50-day avg +8%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
cash, cash equivalents and marketable securities $156.3M Q2 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
LRMR
Larimar Therapeutics, Inc.
this stock
$421.97M +9.2% — — 12.9%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $138.79B +21.9% +46.2% 31.9 1.6%
REGN
Regeneron Pharmaceuticals, Inc.
 $85.30B +8.0% +20.8% 20.5 2.3%
ARGX
Argenx SE
 $63.81B +21.2% — — 1.9%
CSLLY
Csl Ltd
 $60.07B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
161
% held
93.0%
Net QoQ
+8.0M sh
Top holder
DEERFIELD MANAGEMENT COMP…
Held Float
View
Held by Funds
Fund positions
136
View
Short & Settlement
Short Interest Rising
Shares short
13.4M
Days to cover
11.2d
Change
+1.3M sh
View
Short Volume
Short vol %
57%
As of
Aug 25, 2026
Short Total
View
Fails to Deliver
FTD shares
2.3K
Value
$8.5K
As of
Jul 17, 2026
View
Off-Exchange
Off-exchange %
37.8%
Week of
Jul 20, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net buying
Net (90d)
+$166.9K
Buyers / Sellers
1 / 0
Buyers Sellers
View
Financials
Financials
Revenue (FY)
$0
Net income (FY)
$-165.7M
EPS diluted
$-1.32
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 4, 2026
This year
14
View
Proposed Sales
Value
$26.8K
Shares
8.3K
Filed
Jul 24, 2023
View
Exempt Offerings
Offering
$82.1M
Filed
Jun 10, 2020
View
Earnings & Events
Earnings Calls
Last call
May 15, 2023
View

Performance

5D 20D 120D MTD YTD
LRMR +2.5% +8.6% -23.7% +8.9% +9.2%
SPY -0.2% +3.4% +11.8% +2.5% +12.3%
vs SPY +2.7% +5.2% -35.5% +6.4% -3.1%
Key facts CIK 1374690 CUSIP 517125100 13F (30d) 143 filings 143 filers Visit website

Report a Problem

Category
Description
Email (optional, for follow-up)